Fibrobiologics Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.

HOUSTON , March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the progress of a clinical program under development using a fibroblast-based pancreatic beta cell spheroid that secretes insulin in vitro upon glucose stimulation. The development and reproducibility of this work demonstrates that an organoid composed of fibroblasts, beta cells and other components can successfully and durably secrete insulin.

FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment

HOUSTON , March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will present an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, Massachusetts, from April 16-17, 2024. The Advanced Wound Care Summit USA is a forum where industry leaders share the latest innovations and advancements in Wound Care and tackle pressing challenges in areas such as regulation, clinical trials, reimbursement, and investment.

FibroBiologics to Present at Advanced Wound Care Summit USA

HOUSTON , March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel.

FibroBiologics Appoints Ruben A. Garcia as General Counsel

HOUSTON , Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2023, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics' website at https://ir.fibrobiologics.com/sec-filings/annual-reports.

FibroBiologics Files 2023 Form 10-K Annual Report

HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. FibroBiologics will present in vitro and in vivo preclinical data using allogeneic human dermal fibroblasts (HDFs) and HDF spheroids as well as primary safety phase 0/1 clinical trial data for the single-dose infusion of HDFs during the poster sessions at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 on Thursday, February 29, at the Palm Beach County Convention Center and the Hilton West Palm Beach in West Palm Beach, Florida.

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

HOUSTON , Feb. 13, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials encompassing 150+ patents issued and pending, presented preclinical data that employs human dermal fibroblast (HDF) spheroids to treat an induced mouse model of psoriasis at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases during a poster presentation. See the poster "Exploring a Novel Cell-based Therapy Using Human Dermal Fibroblasts in a Mouse Model of Psoriasis" here or on the publications section of the FibroBiologics website.

FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases

HOUSTON , Feb. 8, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of three patents from the United States Patent Office (USPTO) to add to its portfolio. Issued Patents: Patent 11,717,596 (Inventor: Lionel Sevrain) METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR Patent 11,732,239 (Inventor: Pete O'Heeron) TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATION THEREOF Patent 11,819,555 (Inventor: Pete O'Heeron) GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS "As we develop our science, these new patents add to our extensive portfolio of 150+ patents issued and pending, which validate the uniqueness of our potential treatments and processes," said Pete O'Heeron, Chief Executive Officer of FibroBiologics.

FibroBiologics Announces Three United States Patents for Fibroblast Technology

HOUSTON , Feb. 6, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of three patents from the Japan Patent Office (JPO) to add to its portfolio.   Issued Patents: Japanese Patent 7333272, (Inventor: Pete O'Heeron) METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY Japanese Patent 7386162, (Inventor: Pete O'Heeron) AUGMENTATION OF FIBROBLASTS REGENERATIVE ACTIVITY Japanese Patent 7387603, (Inventor: Pete O'Heeron) INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF "Incorporating this additional patent protection into our portfolio reinforces our leadership in this space," said Pete O'Heeron, Chief Executive Officer of FibroBiologics.

FibroBiologics Announces Three Japanese Patents on Fibroblast Technology

Amer Sports Inc

American Healthcare REIT Inc

Alto Neuroscience Inc

Flutter Entertainment PLC

Fractyl Health Inc

Kyverna Therapeutics Inc

Perfect Moment Ltd

BBB Foods Inc

Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of the range to raise $129 million at a $456 million market cap.

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

HOUSTON , Jan. 31, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that trading of the FibroBiologics stock commenced today on Nasdaq under the stock ticker FBLG. The statement was made in connection with FibroBiologics' registration statement on Form S-1 (File No.

FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG

Ai Transportation Acquisition Corp

Agriculture & Natural Solutions Acquisition Corp

Cargo Therapeutics Inc

DDC Enterprise Ltd

Globavend Holdings Ltd

Hamilton Insurance Group Ltd

Shimmick Corp

Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million at a $611 million market cap. Reinsurer and specialty insurance provider Hamilton Group priced below the range to raise $225 million at a $1.7 billion market cap.

U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week

FibroBiologics, Inc. has filed for a Direct Listing of its common stock. The company's lead candidate, CYMS101, has received FDA clearance for a Phase 1/2 clinical trial for degenerative disc disease. The global market for degenerative disc disease treatment is expected to reach $45.9 billion by 2029, driving the growth of the industry.

Biopharma Firm FibroBiologics Seeks U.S. Direct Listing

News for Fibrobiologics Inc Stock (FBLG)